| Literature DB >> 29373915 |
Karim Mashhour1, Maha Kamaleldin, Wedad Hashem.
Abstract
Purpose: The aim of this study was to dosimetrically evaluate and compare double arc RapidArc (RA) with conventional IMRT (7 fields) plans for irradiation of locally advanced head and neck cancers (LAHNC), focusing on target coverage and doses received by organs at risk (OAR).Entities:
Keywords: Dosimetric; double arc; IMRT; MUs
Year: 2018 PMID: 29373915 PMCID: PMC5844619 DOI: 10.22034/APJCP.2018.19.1.207
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Patient and Tumor Characteristics
| Patient | Site | Stage | TNM | Vol PTV 59.4Gy (mL) | Vol PTV 70Gy (mL) |
|---|---|---|---|---|---|
| P1 | Nasopharynx | IV | T2N2 | 565 | 203 |
| P2 | Oropharynx | IV | T3N2b | 513 | 215 |
| P3 | Oropharynx | IV | T4N1 | 530 | 131 |
| P4 | Hypopharynx | III | T3N1 | 720 | 170 |
| P5 | Larynx | IV | T3N2c | 701 | 125 |
| P6 | Larynx | III | T3N0 | 699 | 221 |
| P7 | Oral cavity | IV | T3N2b | 520 | 215 |
| P8 | Larynx | IV | T4N0 | 515 | 150 |
| P9 | Nasopharynx | IV | T2N2 | 570 | 320 |
| P10 | Nasopharynx | IV | T2N2 | 581 | 290 |
| P11 | Larynx | IV | T2N3 | 720 | 180 |
| P12 | Oropharynx | IV | T3N1 | 570 | 151 |
| P13 | Larynx | III | T3N0 | 550 | 170 |
| P14 | Larynx | IV | T4N0 | 613 | 201 |
| P15 | Oral cavity | IV | T3N2b | 545 | 267 |
| P16 | Nasopharynx | IV | T2N2 | 585 | 218 |
| P17 | Hypopharynx | III | T3N1 | 672 | 191 |
| P18 | Larynx | IV | T3N1 | 685 | 220 |
| P19 | Hypopharynx | IV | T3N2 | 691 | 175 |
| P20 | Nasopharynx | IV | T2N2 | 579 | 301 |
Figure 1Dose Distribution for an Axial View Created by Doublearc RA Plan (Top) and a Similar CT Cut Planned by IMRT Technique (Bottom)
Figure 2A Comparative DVHs between IMRT (Triangles) and Double arc RA (Squares). The PTVs are in orange, spinal cord in yellow , brainstem in light blue , the left parotid in purple, right parotid in green and the oral cavity in turquoise.
Dosimetric Outcomes for the PTV70Gy
| Parameter | IMRT | Double arc RA plan | P-value (Independent Student t test) |
|---|---|---|---|
| D98% (Gy) | 69.13 ± 0.17 | 69.82 ± 1.03 | 0.535 |
| D2%(Gy) | 77.15 ± 2.84 | 77.36 ± 1.86 | 0.186 |
| CI95% | 1.05 ± 0.057 | 1.01 ± 0.021 | 0.036 |
| HI | 0.108 ± 0.021 | 0.0975 ± 0.017 | 0.54 |
| MU | 930.5 ± 142.42 | 484.25 ± 69.47 | 0.002 |
Dosimetric Outcomes for the PTV59.4Gy
| Parameter | IMRT | Double arc RA plan | P-value (Independent Student t test) |
|---|---|---|---|
| D98% (Gy) | 61.23 ± 1.147 | 60.93 ± 1.76 | 0.071 |
| D2%(Gy) | 66.56 ± 1.858 | 66.38 ± 1.507 | 0.587 |
| HI | 0.0935 ± 0.030 | 0.0855 ± 0.005 | 0.019 |
Dosimetric Outcomes for the Organs at Risk
| Organ | Parameter | IMRT | Double arc RA plan | P-value (Independent Student t test) |
|---|---|---|---|---|
| Spinal Cord | Max.dose(Gy) | 42.12 ± 2.55 | 40.12 ± 1.93 | 0.013 |
| Brainstem | Max.dose(Gy) | 51.20 ± 9.62 | 50.86 ± 8.47 | 0.046 |
| Right Parotid | Mean dose(Gy) | 20.14 ± 2.15 | 17.95 ± 5.48 | 0.002 |
| Left Parotid | Mean dose(Gy) | 20.48 ± 2.78 | 18.56 ± 2.70 | 0.004 |
| Oral cavity | Mean dose(Gy) | 33.22 ± 3.23 | 31.5 ± 3.45 | 0.043 |